U.S. Preventive Services Task Force*
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Requests for Single Reprints: Reprints are available from the USPSTF Web site (www.preventiveservices.ahrq.gov) and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295).
This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lung cancer and the supporting scientific evidence and updates the 1996 recommendations on this topic. In 1996, the USPSTF recommended against screening for lung cancer (a grade D recommendation). The Task Force now uses an explicit process in which the balance of benefits and harms is determined exclusively by the quality and magnitude of the evidence. As a result, current letter grades are based on different criteria than those used in 1996. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic, available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and the National Guideline Clearinghouse (www.guideline.gov). The complete USPSTF recommendation statement (which includes a brief review of the supporting evidence) and the summary of the evidence are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, firstname.lastname@example.org).
*For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
Appendix Table 1. U.S. Preventive Services Task Force Grades and Recommendations
Appendix Table 2. U.S. Preventive Services Task Force Strength of Overall Evidence
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Daniel K C Lee
Department of Thoracic Oncology, Papworth Hospital, Papworth Everard, Cambridge, CB3 8RE, England
August 23, 2006
10-minute consultation: Suspected lung cancer
A 60-year-old ex-smoker presents to your surgery with mild breathlessness and cough. These symptoms have persisted for about 4 weeks despite treatment with a penicillin antibiotic prescribed by one of your colleagues.
What you need to do
Clinical features requiring an urgent CXR
Any of the following unexplained symptoms or signs persisting more than three weeks
The CXR shows a solitary mass-like shadow in the lung and is reported by a radiologist as being suspicious of lung cancer.
What issues you should cover
Patients with a solitary lung shadow
What you should do
Management of patients with lung cancer: a national clinical guideline. Scottish Intercollegiate Guidelines Network 2005. http://www.sign.ac.uk/pdf/sign80.pdf
Lung cancer: the diagnosis and treatment of lung cancer. National Institute for Clinical Excellence 2005. http://www.nice.org.uk/pdf/CG024niceguideline.pdf
Lung cancer information centre. CancerBACUP 2005. http://www.cancerbacup.org.uk/cancertype/lung
Lung cancer online. Lung Cancer Online Foundation 2005. http://www.lungcanceronline.org
U.S. Preventive Services Task Force*. Lung Cancer Screening: Recommendation Statement. Ann Intern Med. ;140:738–739. doi: 10.7326/0003-4819-140-9-200405040-00014
Download citation file:
Published: Ann Intern Med. 2004;140(9):738-739.
Cancer Screening/Prevention, Guidelines, Hematology/Oncology, Lung Cancer, Prevention/Screening.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use